Drug Sales Trends for savella

Annual Sales Revenues and Units Sold for savella

These sales figures are drawn from a US national survey of drug expenditures

Drug Name	Revenues (USD)	Units	Year
SAVELLA			2021
SAVELLA			2020
SAVELLA			2019
SAVELLA			2018
SAVELLA			2017

Savella Market Analysis and Financial Projection

Market Analysis and Sales Projections for Savella

Introduction to Savella

Savella, also known by its generic name milnacipran, is a medication approved by the U.S. Food and Drug Administration (FDA) for the management of fibromyalgia. It belongs to the class of serotonin-norepinephrine reuptake inhibitors (SNRIs) and is marketed by Forest Laboratories.

Current Market Position

As of the early 2010s, Savella was one of the key players in the fibromyalgia treatment market, alongside Lyrica (pregabalin) and Cymbalta (duloxetine)[1].

Market Share and Sales

• In 2009, Savella was part of the trio of FDA-approved agents driving the fibromyalgia drug market growth. However, it was not the market leader; that position was held by Lyrica, with Cymbalta closely competing for market share[1].
• The market for fibromyalgia treatments, including Savella, was projected to experience a 4.2% annual growth rate from 2009 to 2018, driven by increasing diagnosis rates and the expanding drug-treated population[1].

Challenges and Decline

Generic Erosion

• One of the significant challenges faced by Savella, as well as other branded fibromyalgia drugs, was the impending generic erosion. The entry of generic versions of these drugs was expected to impact sales negatively. For instance, the market was forecasted to decline sharply from $1.8 billion in 2018 to $1.4 billion in 2019 due to the generic entry of pregabalin, which also affected other branded drugs like Savella[1].

Competition

• Savella faced intense competition from other approved therapies, particularly from duloxetine (Cymbalta/Xeristar), which was gaining significant patient share. By 2015, duloxetine was expected to supplant pregabalin as the U.S. patient-share leader, further complicating the market position for Savella[1].

Future Projections

Global Market Growth

• Despite the challenges, the global fibromyalgia treatment market, which includes Savella, is expected to grow. The market is projected to expand from $1.3 billion in 2022 to $2.7 billion by 2033, at a compound annual growth rate (CAGR) of 7.0%[3].

Regional Dynamics

• North America, particularly the U.S., is expected to hold the largest market share during the forecast period due to high prevalence and advanced treatment options. However, the Asia Pacific region is anticipated to grow at the fastest CAGR, driven by increasing awareness and demand for effective treatments[3].

Pipeline and New Therapies

• The introduction of new pipeline agents, including reformulations and "me-too" products, is expected to drive market growth. However, these new products will face competition from generic medicines, which are likely to dominate sales in many regions[5].

Key Takeaways

• Market Growth: The fibromyalgia treatment market, including Savella, is expected to grow at a CAGR of 7.0% from 2022 to 2033.
• Generic Erosion: The entry of generic versions of branded drugs like Savella will continue to impact sales negatively.
• Regional Dynamics: North America will remain a dominant market, while the Asia Pacific region will experience the fastest growth.
• Competition: Savella will continue to face competition from other approved therapies and new pipeline agents.

FAQs

1. What is Savella used for? Savella (milnacipran) is used for the management of fibromyalgia, a chronic condition characterized by widespread pain, fatigue, and other symptoms.

2. How has the market for Savella evolved over the years? The market for Savella has experienced growth driven by increasing diagnosis rates and expanding drug-treated populations. However, it has also faced challenges from generic erosion and competition from other approved therapies.

3. What are the key factors driving the growth of the fibromyalgia treatment market? The growth is driven by increasing research and development expenditures, the approval and launch of novel fibromyalgia treatment drugs, and the high prevalence of fibromyalgia in regions like North America.

4. How does Savella compare to other fibromyalgia treatments like Lyrica and Cymbalta? Savella competes closely with Lyrica and Cymbalta but has faced challenges in maintaining market share due to the strong competition and the impact of generic versions.

5. What are the future projections for the fibromyalgia treatment market? The global fibromyalgia treatment market is expected to grow at a CAGR of 7.0% from 2022 to 2033, reaching a market size of $2.7 billion by 2033.

Sources

1. Decision Resources, Inc. - "Driven by Sales of Lyrica, Cymbalta/Xeristar and Savella, the Fibromyalgia Drug Market Will Experience 4.2 Percent Annual Growth"[1]
2. Allergan plc - "Allergan Reports Fourth Quarter and Full-Year 2018 Financial Results"[2]
3. Persistence Market Research - "Fibromyalgia Treatment Market Size & Growth Forecast, 2033"[3]
4. Coherent Market Insights - "Fibromyalgia Treatment Market, by Drug Class (Antidepressants...)"[4]
5. GlobalData - "Fibromyalgia treatment market value to crawl to $1.9bn by 2023"[5]